Lower Costs for Everyday Americans Act

Improved Recycling Infrastructure: The bill establishes a pilot grant program to help underserved communities improve their access to recycling systems through infrastructure investments (Sec. 102).

Enhanced Drinking Water Safety: Provisions increase funding and extend timelines related to drinking water infrastructure risk and resilience (Sec. 103).

Increased Product Safety: The bill implements consumer product safety standards for certain batteries, specifically for use in light electric vehicles, eBikes, and personal e-mobility devices (Sec. 201, Division B).

Protection Against Nonconsensual Intimate Images: The "TAKE IT DOWN Act" creates a criminal prohibition on the intentional disclosure of nonconsensual intimate visual depictions and establishes a notice and removal process to help individuals remove such content from platforms (Sec. 802, 803, Division B).

Medicaid Accessibility: The bill includes measures to streamline enrollment for eligible out-of-state providers and modify coverage for home or community-based services (Sec. 101, Division C, Title I).

Medicare Proteors: Provisions include the extension of various payments, such as those for ambulance services and acute hospital care at home (Sec. 203, 211, Division C, Title II).

Supply Chain Resilience: The bill aims to promote the stability and resilience of critical supply chains and emerging technologies to strengthen national security (Sec. 402, Division B).

Smart Device Transparency: Manufacturers must clearly disclose if a consumer product has a camera or microphone before a purchase is made (SEC. 1102). This helps people know what features they are buying.

Hotel and Rental Price Clarity: Businesses must display the total price of services, including any fees, at the time a service is first shown (SEC. 1302(a)(1)). This prevents people from being surprised by hidden costs later in the process.

Ticket Price Transparency: Event ticket issuers must display the total price, including all fees, at the start of the purchasing process (SEC. 1402). This ensures consumers see the full cost upfront.

Ticket Refund Protections: If an event is canceled or postponed for more than six months, purchasers are entitled to a full refund or a replacement ticket (SEC. 1405(a)).

Medicaid Provider Access: The bill creates a streamlined enrollment process for eligible out-of-state providers to furnish services to qualifying individuals (SEC. 101(a)).

Expanded Medicaid Support: The law allows for a demonstration program to expand coverage for home and community-based services (SEC. 102(b)).

Increased Pharmacy Price Transparency: The bill requires the Secretary to conduct monthly surveys of retail and non-retail pharmacy drug prices to determine national average acquisition cost benchmarks, which will be made publicly available (Section 112).

Protection Against Abusive Pricing: By requiring a transparent "pass-through" pricing model, the bill ensures that payments for drugs are limited to the actual ingredient cost and a professional dispensing fee, preventing unfair markups (Section 113).

Expanded Cancer Screening Access: The legislation provides coverage for multi-cancer early detection screening tests, allowing for the concurrent detection of multiple cancer types (Section 224).

Improved Home Healthcare Options: The bill expands coverage for external infusion pumps and associated home infusion drugs, provided specific safety and supervision criteria are met (Section 225).

Enhanced Telehealth Access: The act extends various telehealth flexibilities, including the ability to use audio-only services and expanded service locations (Section 209).

Medicare Advantage Directory Accuracy: The bill mandates that Medicare Advantage organizations maintain more accurate provider directories, which helps enrollees find participating providers more easily (Section 223).

Increased Transparency in Pharmacy Benefits: Pharmacy benefit managers must provide written explanations of contracts with drug manufacturers and disclose compensation amounts to PDP sponsors (Section (ii)). This could help ensure that drug coverage and pricing are handled more openly.

Enhanced Audit Rights: PDP sponsors gain the right to conduct annual audits of pharmacy benefit managers to ensure contract compliance and data accuracy (Section (s)(D)(i)).

Support for Fetal Alcohol Spectrum Disorders (FASD): The bill establishes a comprehensive program for the education, prevention, identification, and support of individuals with FASD (Section 514 (a)).

Improved Suicide Prevention Security: It includes steps to protect the National Suicide Prevention Lifeline from cybersecurity incidents to ensure the service remains reliable (Section 518 (a)).

Expanded Community Health Funding: The bill extends and provides new funding for Community Health Centers, the National Health Service Corps, and Teaching Health Centers (Section 401).

Enhanced Pandemic Preparedness: It authorizes funding for wastewater surveillance to detect and monitor infectious diseases, which can help improve public health response (Section 616 (a)).

Improved Diagnostic Capabilities: The bill seeks to increase the development, manufacture, and distribution of diagnostic tests, including high-throughput, point-of-care, and rapid at-home options, to improve accessibility during emergencies (Section (c)(2)).

Combatting Drug Resistance: It establishes a task force to slow the emergence of resistant bacteria and fungi and accelerates research for new antibiotics and antifungals (Section 624(a)(3)).

Strengthened Medical Stockpiles: The bill updates the Strategic National Stockpile to better manage risks, track contents, and ensure efficient deployment of countermeasures (Section 625).

Support for Research Facilities: It authorizes the establishment of at least 12 regional biocontainment laboratories to conduct research and provide surge capacity for responding to biological agents (Section s 629(a)).

Improved Maternal and Infant Health: The bill funds research into preterm labor and delivery, as well as programs aimed at reducing preventable causes of maternal mortality and morbidity (Section 702 and Section 711).

Traumatic Brain Injury Research: It expands the National Program for Traumatic Brain Injury Surveillance and Registries to better identify high-risk populations and study long-term symptoms (Section 705).

Down Syndrome Research: It establishes the INCLUDE Project to research the effects of Down syndrome across the lifespan and improve the quality of life for affected individuals (Section 710).

Increased Drug Price Transparency: It requires pharmacy benefit management entities to provide detailed reports to group health plans regarding drug compensation, costs, and rebates (Section 901).

Increased Transparency in Drug Costs: PBMs must provide detailed reports to group health plans, including information on negotiated prices, rebates, and the difference between what the plan pays and what the pharmacy receives. (Section 726(b)(2)(A))

Full Rebate Pass-Through: Health plans and their participants will benefit from a requirement that 100 percent of all drug-related rebates, fees, and discounts be remitted back to the plan or issuer. (Section 902(a)(1)(C)(i))

Better Understanding of Benefits: Plans are required to provide summary documents to participants and beneficiaries to help them better understand their coverage and benefits. (Section 726(b)(2)(B)(ii))

Improved Generic Drug Clarity: The Secretary of Health and Human Services will now inform applicants if a drug is qualitatively and quantitatively the same as the listed drug, providing specific details if they are not. (Section 903(a)(i))

Telehealth Accessibility: The bill extends the safe harbor for the absence of a deductible for telehealth services through January 1, 2027. (Section 1001)

Banning Certain Consumer Products: The bill classifies any consumer product containing a high concentration of sodium nitrite (10% or more by weight) as a banned hazardous product (Sec. 102, Division B, Title I).

Restrictions on Satellite Access: The bill prohibits the granting of certain satellite licenses or market access to entities that produce or provide covered communications equipment or services (Sec. 702, Division B, Title VII).

Increased Regulation of Batteries: The bill requires the Consumer Product Safety Commission to promulgate specific safety standards for batteries used in light electric vehicles and eBikes (Sec. 201, Division B, Title II).

Speculative Ticketing Restrictions: The bill prohibits those who do not have actual or constructive possession of a ticket from selling or advertising them (SEC. 1403(a)). This could impact certain secondary market business models.

Strict Penalties for Broadband Applicants: High-cost fund applicants face a penalty of at least $9,000 per violation, which may not be less than 30 percent of their total support (SEC. 902(3)(D)).

Financial Penalties for Pharmacies: Retail and non-retail pharmacies face civil money penalties of up to $100,000 for failing to respond to price surveys or providing false information (Section 112).

Increased Administrative Burdens: Pharmacies and Medicare Advantage organizations are subject to new, rigorous reporting, verification, and survey requirements (Sections 112, 223).

Potential Changes to Pharmacy Income: The new regulations regarding PBM contracts and "pass-through" pricing could change how pharmacies are reimbursed for services (Sections 113, 226).

Increased Administrative Burdens on Healthcare Providers: Off-campus outpatient departments must obtain unique health identifiers and submit specific attestations to receive payments (Section 228 (a)).

Potential Financial Penalties for Pharmacy Benefit Managers: Pharmacy benefit managers may be required to reimburse PDP sponsors for civil money penalties resulting from failure to meet specific requirements (Section (2)(A)(ii)).

Cybersecurity Oversight Responsibilities: Local and regional crisis centers are tasked with overseeing the technology they employ for the suicide prevention hotline, which adds a layer of responsibility (Section 518 (c)(3)(A)(i)).

Research Restrictions for Certain Countries: The bill prohibits the funding of research involving enhanced pathogens if conducted by foreign entities in specific "countries of concern," such as China, Russia, and Iran (Section 629A(1)).

Administrative and Reporting Burdens: Various sections, such as the requirements for the Abraham Accords Office and the updates to the Organ Procurement and Transplantation Network, include new reporting and transparency mandates that may increase administrative workloads (Section 811 and Section 712).

Potential Impact on Drug Development: While intended to incentivize research, the bill notes that studies will examine the "burdens on" pediatric cancer drug development resulting from new requirements (Section 801(d)(2)(A)).

Financial Penalties for Non-Compliance: Entities that fail to provide required information or reports may be subject to civil monetary penalties of $10,000 for each day of the violation. (Section 726(d)(2))

Penalties for False Information: Any entity that knowingly provides false information can be fined up to $100,000 per item of false information. (Section 726(d)(3))

Legal Limitations on Patent Litigation: Biological product sponsors are now limited to asserting a maximum of 20 patents in infringement actions against biosimilar applicants. (Section 904(a)(1)(A))